Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 56INDUSTRY 23NETWORK 4OTHER_GOV 3NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Carcinoma, Squamous Cell 1

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Afatinib × Clear all
NCT06709859 2025-07-17

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Shandong Public Health Clinical Center

Phase 2 Recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01156545 2022-04-06

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

National Cancer Center, Korea

Phase 2 Completed
68 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03486509 2018-04-03

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

Fujian Cancer Hospital

Phase 2 Unknown
2 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡